Ramon E. Parsons
Affiliations: | Biochemistry and Molecular Biophysics | Columbia University, New York, NY |
Area:
Molecular Biology, OncologyGoogle:
"Ramon Parsons"Mean distance: (not calculated yet)
Children
Sign in to add traineeKatrina Podsypanina | grad student | 2000 | Columbia |
Danny Liaw | grad student | 2001 | Columbia |
Ian A. Hennessy | grad student | 2002 | Columbia |
John A. Jakob | grad student | 2004 | Columbia |
Amy Gerstein Montia | grad student | 2007 | Columbia |
Lao H. Saal | grad student | 2007 | Columbia |
Barry M. Fine | grad student | 2008 | Columbia |
Cindy Hodakoski | grad student | 2012 | Columbia |
Maira M. Pires | grad student | 2013 | Columbia |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Zhou RW, Parsons RE. (2023) Etiology of super-enhancer reprogramming and activation in cancer. Epigenetics & Chromatin. 16: 29 |
Kabir M, Sun N, Hu X, et al. (2023) Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53. Journal of the American Chemical Society |
Cahuzac KM, Lubin A, Bosch K, et al. (2023) AKT activation because of PTEN loss upregulates xCT via GSK3β/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells. Cell Reports. 42: 112536 |
Zhou RW, Xu J, Martin TC, et al. (2022) A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. Nature Communications. 13: 6041 |
Yu X, Xu J, Cahuzac KM, et al. (2022) Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells. Journal of Medicinal Chemistry |
Schoenfeld DA, Zhou R, Zairis S, et al. (2022) Loss of PBRM1 alters promoter histone modifications and activates ALDH1A1 to drive renal cell carcinoma. Molecular Cancer Research : McR |
Yu X, Xu J, Xie L, et al. (2021) Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders. Journal of Medicinal Chemistry |
Xu J, Yu X, Martin TC, et al. (2021) AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild-type KRAS and BRAF by destabilizing Aurora kinase B. Cancer Discovery |
Pappas K, Martin TC, Wolfe AL, et al. (2021) NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer. Communications Biology. 4: 312 |
Molina-Sánchez P, Ruiz de Galarreta M, Yao MA, et al. (2020) Cooperation between distinct cancer driver genes underlies inter-tumor heterogeneity in hepatocellular carcinoma. Gastroenterology |